NCT03361436 2026-04-08
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
14 trialsNCT06006273 2025-11-10
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06957431 2025-10-24
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Washington University School of Medicine
Phase 1 Recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01795586 2022-10-31
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03579472 2022-10-31
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02120469 2022-07-05
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03502681 2022-07-01
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Big Ten Cancer Research Consortium
Phase 1 Terminated
NCT02824575 2022-04-04
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Montefiore Medical Center
Phase 1 Terminated
NCT02596503 2022-02-15
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
Phase 1 Completed
NCT01802970 2021-10-08
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Baylor Research Institute
Phase 1 Completed
NCT03430518 2020-08-05
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02082626 2020-03-10
ERIBULIN
University of Oklahoma
Phase 1 Terminated
NCT02616848 2015-11-30
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Istituti Ospitalieri di Cremona
Phase 1 Unknown